A House panel has officially subpoenaed Martin Shkreli, the former hedge fund manager whose price hike of a needed drug caused a public backlash.
The House Oversight Committee sent a subpoena to Shkreli on Jan. 11 to attend a Tuesday hearing, but it is not clear if Shkreli will attend. The former CEO of Turing Pharmaceuticals was arrested in December for securities fraud charges unrelated to the 5,000 percent price increase of Daraprim, an anti-parasite treatment. He resigned shortly after his arrest.
House lawmakers took aim at Shkreli, saying the subpoena is a long time coming.
“I have been trying for the better part of a year to get information from Martin Shkreli about his outrageous price increases, and he has obstructed our investigation at every turn,” said Rep. Elijah Cummings of Maryland, the top Democrat on the committee. “He claims publicly that he wants to explain to Congress how drug pricing works. On Tuesday, he will get his chance.”
Shkreli took to social media to jab the subpoena, saying that he hasn’t decided whether he will attend.
